Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 02/25/26
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides UpdateBusiness Wire • 11/14/25
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease SymposiumBusiness Wire • 09/15/25
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B StudyBusiness Wire • 06/23/25
All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to BuyZacks Investment Research • 04/03/25
Forte Biosciences (FBRX) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 01/03/25
Here's Why Momentum in Forte Biosciences (FBRX) Should Keep goingZacks Investment Research • 11/28/24
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune IndicationsBusiness Wire • 11/20/24
Forte Biosciences (FBRX) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 11/19/24
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business UpdateBusiness Wire • 11/14/24
Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business UpdateBusiness Wire • 08/14/24
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business UpdateBusiness Wire • 05/13/24
Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business UpdateBusiness Wire • 11/13/23